This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PRNB Principia Biopharma (PRNB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Principia Biopharma Stock (NASDAQ:PRNB) 30 days 90 days 365 days Advanced Chart Get Principia Biopharma alerts:Sign Up Key Stats Today's Range$100.05▼$100.0550-Day Range$99.95▼$100.2752-Week Range$25.35▼$101.89VolumeN/AAverage Volume729,676 shsMarket Capitalization$3.32 billionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Principia Biopharma Inc., a late-stage biopharmaceutical company, focuses on developing novel therapies for immunology and oncology. The company is developing PRN1008, an inhibitor that is in Phase III clinical trial for the treatment of pemphigus, a chronic skin disease, as well as in Phase II clinical trial to treat immune thrombocytopenic purpura. It is also developing PRN2246/SAR442168, an inhibitor, which has completed Phase I clinical trial for treating multiple sclerosis (MS) and other central nervous system (CNS) diseases; PRN1371, a drug candidate that is in Phase I clinical trial for the treatment of solid tumors; and oral small molecule inhibitors of the immunoproteasome. The company has a collaboration agreement with Genzyme Corporation to develop relapsing and progressive MS and other diseases of the CNS. Principia Biopharma Inc. was incorporated in 2008 and is headquartered in South San Francisco, California. Read More Receive PRNB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Principia Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address PRNB Stock News HeadlinesSports Final: Maty Mauk ready to coach Principia High SchoolApril 25, 2025 | msn.comFORE Biotherapeutics Names Michael Byrnes as Chief Financial OfficerAugust 12, 2024 | finance.yahoo.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.July 12 at 2:00 AM | Brownstone Research (Ad)Principia College names new presidentMay 28, 2023 | bizjournals.comCBI appoints ethics consultancy Principia Advisory in fight for survivalMay 5, 2023 | theguardian.comTruist Securities Downgrades 9 Meters Biopharma to Hold, Announces $38 Price TargetMarch 22, 2023 | benzinga.comWooly mammoth tusk discovered on Principia College campusJanuary 17, 2023 | msn.comDodge Construction Network Acquires Principia Consulting, Expanding Dodge Advisory Services’ CapabilitiesOctober 12, 2022 | finance.yahoo.comSee More Headlines PRNB Stock Analysis - Frequently Asked Questions How were Principia Biopharma's earnings last quarter? Principia Biopharma Inc. (NASDAQ:PRNB) posted its earnings results on Thursday, August, 6th. The company reported $0.31 earnings per share for the quarter, beating the consensus estimate of ($1.03) by $1.34. The business had revenue of $50 million for the quarter, compared to analysts' expectations of $50 million. When did Principia Biopharma IPO? Principia Biopharma (PRNB) raised $75 million in an IPO on Friday, September 14th 2018. The company issued 4,700,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch, Leerink Partners and Wells Fargo Securities acted as the underwriters for the IPO and Baird was co-manager. What other stocks do shareholders of Principia Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Principia Biopharma investors own include Pfizer (PFE), Advanced Micro Devices (AMD), AbbVie (ABBV), Bristol Myers Squibb (BMY), Cisco Systems (CSCO), QUALCOMM (QCOM) and VBI Vaccines (VBIV). Company Calendar Last Earnings8/06/2020Today7/12/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:PRNB CIKN/A Webwww.principiabio.com Phone650-416-7700FaxN/AEmployees65Year FoundedN/AProfitability EPS (Trailing Twelve Months)($2.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$53.79 million Net MarginsN/A Pretax MarginN/A Return on Equity-23.08% Return on Assets-21.11% Debt Debt-to-Equity RatioN/A Current Ratio17.01 Quick Ratio17.01 Sales & Book Value Annual Sales$35.16 million Price / Sales94.50 Cash FlowN/A Price / Cash FlowN/A Book Value$10.95 per share Price / Book9.14Miscellaneous Outstanding Shares33,209,000Free FloatN/AMarket Cap$3.32 billion OptionableNot Optionable Beta0.86 The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:PRNB) was last updated on 7/12/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get PaidBank of America believes gold could hit $4,000 an ounce in the next 12 months. That's an 18% jump from toda...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Principia Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Principia Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.